Introducing Malaysia to medically supervised use of nicotine vaping products (NVPs)

A new tool to aid smoking cessation and nicotine dependence

Lumelife Malaysia

Exclusive distributor in Malaysia of the Nicovape® Q range of NVP products

NVP use as a cessation therapy

January 2024’s Cochrane Collaboration states that:

“there is high-certainty evidence that NVPs increase quit rates compared to nicotine replacement therapy (NRT) and moderate-certainty evidence that they increase quit rates compared to vaping products without nicotine”.

NVPs may be particularly useful for patients who have a history of failed quit attempts using other therapies.

Nicovape® Q is exclusively for therapeutic use by medical practitioners

Australia is the first country to establish a therapeutic access pathway to vaping to for smoking cessation.

Nicovape® Q is the first, and remains the only, NVP distributed exclusively under medical prescription globally. 

Prescribers have used Nicovape® Q to help thousands of patients stop smoking and vaping permanently.

Developed and manufactured to the standards expected of medical devices

Liber’s Nicovape® Q offers prescribers an NVP that:

  • Is appropriate as a medical device for smoking cessation and the management of nicotine dependence; and 
  • Is free from the moral and ethical considerations arising from tobacco industry involvement 
  • Has never been sold as a consumer product in Malaysia or globally.

Have all other quit attempts failed?

For patients with a history of failed attempts to stop smoking, the therapeutic use of NVPs, particularly when coupled with ongoing support, shows great promise.

Latest news:

Customer portal

Are you interested to prescribe NVP Product?

Healthcare professionals

Are you interested to learn more on NVPs in a Medical Framework?

Scroll to Top